In this episode, we hear from Dr Scott DeWire, Head of US Business Development at Boehringer Ingelheim (BI) and Dr Andrew Fadden, Head of Corporate Development at Enara Bio about the power of research partnerships in progressing cancer innovation and drug development. Their discussion proves that embracing collaboration is essential in delivering ground-breaking treatments to patients, faster. What do pharmaceutical partnerships entail? What can we gain from collaborating with partners? Do we share the same goals? Listen to this episode to find out more!

In episode 2, our host Sebastian discusses all things clinical with those who have deep insights from personal experience: Ivy Elkins, co-founder of EGFR-Resisters, lung cancer survivor and patient advocate, as well as Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology Medicine at Boehringer Ingelheim. Do physicians and patients see things in the same light? Listen-in!

In our first episode of the series, Sebastian Hermelin speaks to Dr. Darryl McConnell, Research Site Head at Boehringer Ingelheim Vienna, about targeting ‘undruggable’ cancers and how his team are working tirelessly to find solutions to one of the most challenging areas of cancer research.